真菌感染疾病诊断市场：依诊断技术、最终用户、检体类型、病原体类型和检测方式划分－2025-2032年全球预测

预计到 2032 年，真菌感染疾病诊断市场将成长至 38.9 亿美元，复合年增长率为 7.17%。

关键市场统计数据
基准年 2024	22.3亿美元
预计年份：2025年	24亿美元
预测年份 2032	38.9亿美元
复合年增长率 (%)	7.17%

全面介绍现代真菌诊断、临床负担、诊断缺口以及对更快更准确检测方法的需求

真菌感染疾病的临床和诊疗紧迫性日益凸显，因为这些病原体在各种医疗环境中持续引发诊断难题。临床医生面临持续的挑战，因为真菌感染疾病的症状通常与细菌和病毒感染相似，但所需的治疗策略却截然不同。诊断延迟或不准确会直接导致患者预后不良、住院时间延长以及抗菌药物抗药性风险增加，所有这些都凸显了快速、准确诊断的重要性。

在此背景下，诊断领域的相关人员正在探索一套快速发展的套件，涵盖从传统培养方法到先进的分子和蛋白质体学平台。实验室和医院正在权衡基于培养方法的可靠性、分子诊断的快速性以及质谱技术的通量优势。同时，就地检验正逐渐成为集中式工作流程的补充，尤其是在门诊和资源匮乏的环境中，快速决策至关重要。

随着诊断技术的日益多样化，决策者必须在预算有限且复杂的报销机制下，仔细权衡分析性能、临床效用、通量和成本。因此，临床实验室、研究机构和医院网路都在优先考虑符合自身能力和病患群体需求的实施方案。本导言旨在为后续分析提供框架，重点阐述影响真菌诊断近期投资和政策选择的临床需求、技术权衡和营运考量。

分子诊断、蛋白质体学、自动化、就地检验和数据驱动的临床整合方面的进步正在改变真菌诊断模式。

由于技术、操作和数据驱动等多面向因素的融合，真菌诊断领域正经历变革性的转变。分子诊断技术加速了从表型鑑定向基因型和序列表征的转变，不仅实现了病原体的快速检测，还提供了更丰富的抗药性决定因素和菌株水平突变资讯。同时，MALDI-TOF MS等质谱技术透过缩短鑑定时间和减少技术人员的操作时间，重新定义了实验室工作流程；而显微镜和培养流程的改进则持续提供关键的确认性诊断和药敏试验数据。

除了检测效能之外，自动化和实验室资讯学正在集中资料流，并实现分散式检查实验室网路中更一致的工作流程。实验室资讯系统与临床决策支援的整合正在改善结果解读，并促进更具可操作性的报告，从而缩短从检测到治疗优化的时间。同时，就地检验和侧向层析免疫检测的成熟正在将诊断范围扩展到门诊和急诊科，使患者能够即时获得检测结果，从而做出及时的抗真菌药物治疗决策。

定序技术的进步，特别是次世代定序（NGS）调查方法的进步，为全面分析病原体和集体爆发调查开闢了新的可能性。 NGS化学方法的改进、平台可用性的提高以及生物资讯学流程的完善，使得诊断实验室能够利用深度定序来表征复杂的感染疾病和混合感染族群。然而，当临床问题较为具体且结果出炉时间至关重要时，透过即时PCR或常规PCR进行标靶快速检测仍不可或缺。

最后，将数位健康工具和人工智慧整合到真菌诊断中，正开始影响基于影像的解读、预测风险分层和工作流程优化。这些变化并非只是渐进式的改进，而是诊断路径的重构，速度、特异性和整合资料输出的重要性日益凸显，并逐渐决定临床应用和实验室投资的优先顺序。

评估2025年美国关税对全球真菌诊断供应链、采购经济和创新轨蹟的累积影响

关税等政策措施会对诊断供应链、采购惯例和创新生态系统产生深远且有时被低估的连锁反应。 2025年，美国对某些进口商品征收关税，影响了真菌检测流程中必不可少的诊断设备、耗材和试剂的成本结构。对于依赖全球供应商网路的临床实验室和医院系统而言，进口成本的增加正在影响其采购决策，并加速其供应商关係多元化的进程。

采购团队正在透过审查供应商组合、尽可能合併订单以及寻找国内关键零件製造商来应对关税带来的价格波动风险。这些调整会对营运产生影响：检验的替代供应商必须重新获得资格，产品替代可能会影响工作流程效率和诊断的连续性。在研究环境中，试剂成本的上涨使研究设计和预算编制变得更加复杂，这可能会减缓转化研究的进展，并延迟产生可用于支援临床应用的检验数据。

关税也在影响製造商的创新策略。一些供应商正透过投资近岸外包和本地製造来重组供应链，以确保产品供应并保持价格竞争力。另一些供应商则加速产品系列转型，转向更节能高效的平台和整合系统，从而减少对高关税组件的依赖。从市场观点，这些变化可能会影响实验室向下一代平台迁移的速度，并重塑客户与供应商之间关于基于数量的定价和多年服务合约的谈判结构。

重点，监管和报销框架将与关税的影响相互作用。除非临床疗效得到明确证实，否则医疗支付者和医院可能会推迟核准高成本的诊断产品，这凸显了进行可靠的临床效用研究的重要性。摘要，关税正在促使各方在采购、检验、生产策略和证据生成等方面做出多方面的应对，而那些积极调整供应链和临床证据策略的相关人员将更有利于维持服务品质和创新势头。

关键细分洞察，整合诊断技术、最终用户、检体类型、病原体谱和检测模式，指南策略优先排序。

要了解市场，需要对诊断技术进行详细分析，并了解每种方法如何应用于临床案例和实验室实践。以培养为基础的方法是许多实验室的临床基石，液体和固态培养基培养为基于生长的确认和抗真菌药物敏感性测试提供了机会。免疫检测（包括酵素连结免疫吸附试验 (ELISA) 平台和横向流动化验）透过抗原和抗体检测支持快速临床分流和监测，这在资源有限和照护现场环境中尤其有用。基质辅助雷射解吸电离飞行时间质谱 (MALDI-TOF MS) 可显着缩短培养分离株的鑑定时间，从而减少人力投入并加快后续临床决策。在许多医疗机构中，显微镜检查仍然是快速初步诊断的关键，尤其是在形态学观察支持即时选择治疗方案的情况下。分子诊断涵盖了次世代定序(NGS) 和聚合酵素链锁反应(PCR) 的方法。在新一代定序（NGS）领域， 定序和 Ion Torrent定序在读取准确性、通量和运行时间方面提供了互补的优势，从而能够进行全面的病原体分析和疫情爆发分析。在 PCR 领域，常规和即时聚合酵素链锁反应聚合酵素链锁反应可在既定的临床工作流程中提供高度定向和灵敏的检测。

最终用户包括诊断实验室、医院/诊所和研究机构，它们在技术应用和投资方面各有不同的动机。诊断实验室优先考虑兼顾通量、单次检测成本和与实验室资讯系统整合性的平台。而医院和诊所则倾向于能够快速获得结果、直接影响病患管理的方案。研究机构则优先考虑表征的深度和探索性检测的灵活性，并且通常是先进定序和蛋白质组学方法的早期采用者。

检体类型，包括血液、脑脊髓液、痰液、组织和尿液，决定了分析要求和分析前流程。鑑于感染疾病和中枢神经系统感染疾病的临床严重，血液和脑脊髓液检测需要高灵敏度的分析方法和严格的污染控制。呼吸道检体，例如痰液和组织样本，涉及更复杂的检体处理，通常受益于结合培养和分子检测的工作流程。尿液检查在侵袭性疾病中较少见，但在某些监测和门诊环境中非常有用。

按病原体类型（曲菌症、念珠菌症、隐球菌病、皮肤丝状菌症和白霉菌症）进行分类，可指导诊断靶向，因为每种属和临床综合征都存在不同的分析挑战、抗药性特征和检体选择偏好。检测模式涵盖临床检测、就地检验和仅用于研究的应用，反映了从临床可操作诊断到探索性和研究性检测的频谱。综合考虑这些分类维度，可以指导技术开发、监管规划和商业化路径的策略优先排序，因为灵敏度、速度和操作适用性之间的权衡因细分指南和用户群体而异。

区域趋势和竞争定位（美洲、欧洲、中东和非洲、亚太地区）重点关注采用率、监管和容量趋势

区域趋势既影响技术采纳的速度，也影响诊断服务提供的结构。在美洲，高通量参考实验室和综合医疗系统推动了对高通量平台和整合工作流程的需求，而强大的临床研究网络则支援路径检验以及定序和质谱技术的早期应用。然而，由于报销机制的复杂性和区域采购模式的限制，在三级医疗中心以外的广泛推广之前，必须明确证明其临床效用和成本效益。

欧洲、中东和非洲地区医疗基础设施的多样性造成了市场结构的两极化。儘管都市区和三级医疗机构的先进实验室已部署了尖端的分子和蛋白质组学平台，但许多机构仍依赖传统的培养和免疫检测流程。欧洲部分地区的监管协调工作将有助于跨境应用，但整个地区报销环境的差异和检测能力的差异，使得产品设计需要适应性强，并提供有针对性的实施支援。

在亚太地区，对检测能力的快速投资以及对感染疾病防治的日益重视，为集中式和分散式诊断技术的发展创造了有利条件。该地区的市场动态受到大规模公共医疗采购和私人实验室扩张的双重驱动，这为能够扩大供应规模并提供培训和检验支援的製造商创造了机会。在所有地区，在地化生产、供应链韧性和监管一致性正日益成为影响采购週期和新技术融入常规临床实践速度的关键因素。

真菌诊断生态系统主要企业的企业资料和策略，包括创新路径、伙伴关係和商业化策略。

竞争格局呈现出多元化的特点，既有成熟的仪器和试剂製造商，也有专业的分子和定序平台提供者、受託研究机构，以及新兴的软体和数据分析公司。市场领导凭藉整合解决方案脱颖而出，这些方案将强大的仪器平台与检验的耗材、软体驱动的工作流程编排以及能够减轻客户检验负担的服务协议相结合。中型公司则通常专注于针对特定实验室领域、照护现场模式或经济高效的耗材模式的利基检测产品。

策略联盟和经销伙伴十分普遍，使公司能够拓展地域覆盖范围，并整合互补技术，例如将质谱鑑定係统与分子抗药性检测相结合。此外，Start-Ups公司正专注于一些创新领域，例如简化样品製备、提高灵敏度的快速侧向层析技术以及简化NGS分析的生物资讯工具。合约实验室和参考检测网路作为早期采用者和检验发挥关键作用，为新技术展现临床效用并促进其在实验室中的广泛应用铺平了道路。

一个清晰的趋势正在显现：投资于证据生成、监管合规准备和可扩展服务模式的公司，在与医疗系统签订长期合约方面占据优势。此外，能够提供培训、远端支援以及与实验室资讯系统 (LIS) 整合的公司，可以减轻客户负担并加速产品应用。竞争优势越来越取决于能否提供端到端的解决方案，全面应对分析性能、营运效率、实验室检验和临床医生应用等方面的实际挑战。

为产业领导者提供切实可行的建议，以加速临床应用、加强供应链、优化产品组合併在诊断领域创造价值。

产业领导者应优先采取一系列策略行动，在控制营运风险的同时，加速临床应用。首先，投资进行有针对性的临床效用研究，将诊断结果与可操作的治疗决策和可衡量的患者疗效联繫起来。强有力的临床证据将降低支付方的阻力，并支持更广泛的应用。其次，实现供应链多元化，并考虑区域性生产和策略性库存缓衝，以降低关税和物流风险。这将确保即使在政策变动期间，检测服务的持续性。

第三，我们将透过提供模组化平台，使产品开发与终端用户的工作流程保持一致，该平台既能满足高通量集中检测的需求，也能满足快速照护现场的需求。这种方法将增加可套用场景的数量，并使实验室能够根据自身的侦测量扩展应用规模。第四，我们将透过加强与参考实验室和临床网路的合作，加快产品推广速度，从而促进第三方检验、早期应用案例记录和临床医生培训。第五，我们将把软体主导的价值提案（例如连接性、结果解读和工作流程自动化）融入我们的产品中，以减轻实验室的负担，并提高检测结果对临床医生的效用。

最后，应积极主动地与监管机构和支付方沟通，在研发初期就明确证据要求和报销途径。预先考虑监管和报销方面的问题，并将真实世界证据的收集纳入产品上市流程，可以加快产品上市速度，并减少推广应用的障碍。这些措施共同建构了一个稳健的商业策略，在创新、证据生成和业务连续性之间取得了平衡。

透明的调查方法，清楚地概述了主要和次要调查方法、资料三角验证、检验通讯协定以及支撑分析的分析限制。

本分析基于混合方法研究，整合了初步质性研究、系统性二手证据回顾和三角验证。初步研究包括对临床实验室技术人员、医院采购人员、研究人员和行业高管进行结构化访谈，以收集有关工作流程、检验障碍和推广驱动因素的经验性见解。二手研究涵盖同行评审文献、监管指导文件、临床实践指南和技术白皮书，以阐明初步研究结果并检验分析假设。

数据三角测量法用于整合不同的输入数据，并识别相关人员群体和证据来源之间的一致模式。透过技术映射和能力评估，使平台属性与临床应用案例和实验室操作限制相符。此外，对临床试验註册资讯和专利申请的审查，补充了对新兴检测方法的创新轨迹和未来展望。

本研究认识到定性资料和二手资料固有的局限性，包括区域报告差异、不断变化的监管环境以及技术发展与临床检验发表之间的时间滞后。为弥补这些局限性，分析重点关注已证实的主题，并区分观察到的实践与理想能力。在适当情况下，我们会考虑区域差异和机构能力，以确保建议在不同的医疗环境中均具有可操作性。

简洁扼要的结论总结了临床医生、实验室主任、投资者和政策制定者在应对不断变化的真菌诊断格局方面所应遵循的原则。

随着技术创新、供应链重组和实证实践的融合，真菌诊断正在经历一场深刻的变革，重塑临床实践。实验室和医疗机构面临复杂的抉择，需要在分析绩效、营运实际情况和支付方期望之间取得平衡。随着分子和蛋白质体学平台日趋成熟，就地检验的普及，成功的解决方案不仅要展现出切实的临床效益，还要能够无缝整合到现有工作流程中。

政策和采购因素，例如关税和区域製造业趋势，将继续影响投资和应用模式。积极应对这些因素的相关人员，例如透过多元化采购、策略联盟和重点证据生成，可以维持诊断服务的连续性并加速创新技术的应用。最终，将製造商、临床领导者和医疗系统聚集在一起，共同检验、采用和优化真菌感染疾病诊断路径的协作方式，将是持续进展的关键。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 将快速分子诊断试剂盒整合到医院常规诊疗流程中，以实现真菌病原体的检测。
• 利用次世代定序技术全面鑑定罕见和抗药性真菌物种
• 开发用于门诊早期检测侵袭性真菌感染疾病的即时免疫检测照护现场
• 对能够同时检测临床检体中多种真菌病原体的多重PCR技术的需求日益增长
• 扩展远端医疗平台，整合远距离诊断工具，用于监测慢性真菌感染疾病
• 人们对床边检测HIV患者隐球菌抗原的横向流动化验越来越感兴趣
• 监管核准和报销政策促进了新型β-D-聚葡萄糖诊断测试的市场准入

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 真菌感染疾病诊断市场（依诊断技术划分）

• 培养方法
  • 液体培养基培养
  • 固体培养基培养
• 免疫检测
  • ELISA
  • 横向流动化验
• MALDI TOF MS
• 显微镜
• 分子诊断
  • 次世代定序
    • Illumina定序
    • 离子流定序
  • 聚合酵素链锁反应
    • 常规聚合酵素链锁反应
    • 即时聚合酵素链锁反应

第九章 依最终用户分類的真菌感染疾病诊断市场

• 诊断实验室
• 医院和诊所
• 研究所

第十章：依检体类型分類的真菌感染疾病诊断市场

• 血
• 脑脊髓液
• 痰
• 组织
• 尿

第十一章 以病原体类型分類的真菌感染疾病诊断市场

• 曲菌症
• 念珠菌症
• 隐球菌病
• 皮肤丝状菌症
• 白霉菌症

第十二章 依检测方法分類的真菌感染疾病诊断市场

• 实验室检测
• 就地检验
• 仅供研究使用

第十三章 真菌感染疾病诊断市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 真菌感染疾病诊断市场（按组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国真菌感染疾病诊断市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Thermo Fisher Scientific Inc.
  • Roche Holding AG
  • Abbott Laboratories
  • bioMerieux SA
  • Becton, Dickinson and Company
  • Bruker Corporation
  • DiaSorin SpA
  • QIAGEN NV
  • Siemens Healthineers AG
  • Fujirebio Holdings, Inc.

The Fungal Infections Diagnosis Market is projected to grow by USD 3.89 billion at a CAGR of 7.17% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 2.23 billion
Estimated Year [2025]	USD 2.40 billion
Forecast Year [2032]	USD 3.89 billion
CAGR (%)	7.17%

Comprehensive introduction to contemporary fungal diagnostics, framing clinical burdens, diagnostic gaps, and the imperative for faster, more precise detection

The clinical and operational urgency around fungal infections has intensified as these pathogens continue to present diagnostic complexity across diverse care settings. Clinicians face a persistent challenge: fungal disease often mimics bacterial and viral syndromes while requiring fundamentally different therapeutic strategies. Delays or inaccuracies in diagnosis translate directly into adverse patient outcomes, extended hospital stays, and amplified antimicrobial resistance risks, which together raise the stakes for faster and more precise diagnostics.

Against this backdrop, diagnostic stakeholders are navigating a rapidly evolving toolkit that spans traditional culture methods to advanced molecular and proteomic platforms. Laboratories and hospitals are balancing the reliability of culture-based approaches with the speed advantages of molecular diagnostics and the throughput benefits of mass spectrometry technologies. At the same time, point-of-care testing is emerging as a complement to centralized workflows, particularly in outpatient and resource-limited environments where rapid decision-making is critical.

As diagnostic technologies diversify, decision-makers must weigh analytical performance, clinical utility, throughput, and cost within constrained budgets and complex reimbursement landscapes. Clinical laboratories, research institutes, and hospital networks are therefore prioritizing adoption pathways that align with institutional capabilities and patient populations. This introduction frames the subsequent analysis by highlighting the clinical imperatives, technology trade-offs, and operational considerations that will shape near-term investment and policy choices in fungal diagnostics.

Transformative shifts in fungal diagnostic landscape driven by molecular advances, proteomics, automation, point-of-care evolution, and data-driven clinical integration

The landscape of fungal diagnostics is undergoing transformative shifts driven by converging technological, operational, and data-centric forces. Molecular diagnostics have accelerated the move from phenotype-based identification toward genotypic and sequence-based characterization, enabling not only quicker pathogen detection but also richer information about resistance determinants and strain-level variation. Concurrently, mass spectrometry technologies such as MALDI TOF MS have redefined laboratory workflows by compressing identification timelines and reducing hands-on technician time, while improvements in microscopy and culture workflows continue to provide essential confirmatory and susceptibility data.

Beyond assay performance, automation and laboratory informatics are centralizing data flows and enabling more consistent workflows across decentralized laboratory networks. Integration of laboratory information systems with clinical decision support is improving result interpretation and driving more actionable reporting, thereby shortening the time from detection to therapy optimization. In parallel, the maturation of point-of-care modalities and lateral flow immunoassays is expanding diagnostic reach into outpatient clinics and emergency departments, where immediate results can drive timely antifungal stewardship decisions.

Advances in sequencing, particularly in Next Generation Sequencing methodologies, are unlocking new capabilities for comprehensive pathogen profiling and outbreak investigation. Improvements in NGS chemistry, platform accessibility, and bioinformatics pipelines are making deep sequencing feasible for diagnostic laboratories seeking to characterize complex infections or mixed populations. At the same time, real-time PCR and conventional PCR remain indispensable for targeted, rapid detection when clinical questions are narrow and turnaround time is critical.

Finally, the integration of digital health tools and artificial intelligence into fungal diagnostics is beginning to influence image-based interpretation, predictive risk stratification, and workflow optimization. Together, these shifts are not incremental; they represent a reconfiguration of diagnostic pathways, where speed, specificity, and integrated data outputs will increasingly determine clinical adoption and laboratory investment priorities.

Assessing the cumulative impact of United States tariffs in 2025 on global fungal diagnostics supply chains, procurement economics, and innovation trajectories

Policy instruments such as tariffs can have broad and sometimes underappreciated ripple effects across diagnostic supply chains, procurement practices, and innovation ecosystems. In 2025, United States tariffs introduced on selected imports are influencing cost structures for diagnostic instruments, consumables, and reagents that are integral to fungal testing workflows. For clinical laboratories and hospital systems that rely on global supplier networks, incremental import costs are shaping purchasing decisions and accelerating efforts to diversify vendor relationships.

Procurement teams are responding by recalibrating supplier mixes, increasing order consolidation where possible, and exploring domestic manufacturers for critical components to mitigate exposure to tariff-driven price volatility. These adaptations carry operational implications: validated alternative suppliers require requalification, and product substitutions can affect workflow efficiency and diagnostic continuity. In research settings, higher reagent costs are complicating study design and budget planning, which in turn can slow translational research efforts and delay the generation of clinical validation data that underpins adoption.

Tariffs are also influencing innovation strategies among manufacturers. Some vendors are reshaping supply chains through near-shoring and localized manufacturing investments to preserve competitive pricing while maintaining product availability. Others are accelerating product portfolios toward consumable-efficient platforms or integrated systems that reduce dependency on high-tariff components. From a market perspective, these shifts may alter the pace at which laboratories upgrade to next-generation platforms, and they may reshape negotiations between customers and suppliers around volume-based pricing and multi-year service agreements.

Importantly, regulatory and reimbursement frameworks interact with tariff impacts. Healthcare payers and hospitals may be slower to approve higher-cost diagnostics absent clear evidence of improved clinical outcomes, which places a premium on robust clinical utility studies. In summary, tariffs are prompting a multi-dimensional response that spans procurement, validation, manufacturing strategy, and evidence generation, and stakeholders that proactively adapt their supply chain and clinical evidence strategies will be better positioned to sustain service quality and innovation momentum.

Key segmentation insights synthesizing diagnostic technologies, end users, specimen types, pathogen profiles, and testing modes to guide strategic prioritization

Understanding the market requires a granular view of diagnostic technologies and how each modality maps to clinical use cases and laboratory operations. Culture Based approaches remain the clinical backbone for many laboratories, with liquid broth culture and solid media culture providing growth-based confirmation and the opportunity for antifungal susceptibility testing. Immunoassays, including Elisa platforms and lateral flow assay formats, deliver antigen and antibody detection that supports rapid clinical triage and surveillance, particularly in resource-constrained or point-of-care settings. MALDI TOF MS has materially lowered time-to-identification for cultured isolates, reducing labor and accelerating downstream clinical decision-making. Microscopy continues to be indispensable for rapid presumptive diagnosis in many care environments, particularly when morphology informs immediate therapeutic choices. Molecular Diagnostics encompass both Next Generation Sequencing and Polymerase Chain Reaction based approaches. Within NGS, Illumina Sequencing and Ion Torrent Sequencing offer complementary trade-offs between read accuracy, throughput, and run time, enabling comprehensive pathogen profiling and outbreak analytics. Within PCR, Conventional Polymerase Chain Reaction and Real Time Polymerase Chain Reaction provide targeted, highly sensitive detection with well-established clinical workflows.

End users include Diagnostic Laboratories, Hospitals & Clinics, and Research Institutes, each with distinct drivers for technology adoption and investment. Diagnostic laboratories prioritize platforms that balance throughput, cost-per-test, and integration with laboratory information systems, while hospitals and clinics often favor rapid-turnaround modalities that can directly influence patient management. Research institutes focus on depth of characterization and flexibility for exploratory assays, often serving as early adopters for advanced sequencing and proteomic methods.

Specimen types such as blood, cerebrospinal fluid, sputum, tissue, and urine frame analytical requirements and pre-analytical workflows. Blood and cerebrospinal fluid demand assays with high analytical sensitivity and contamination control given the clinical severity of bloodstream and central nervous system infections. Respiratory specimens like sputum and tissue samples introduce complexity in sample processing and often benefit from combined culture and molecular workflows. Urine-based testing, while less common for invasive disease, is valuable in certain surveillance and outpatient contexts.

Pathogen-type segmentation-including Aspergillosis, Candidiasis, Cryptococcosis, Dermatophytosis, and Mucormycosis-drives diagnostic target selection, as each genus and clinical syndrome has different analytic challenges, resistance profiles, and specimen preferences. Testing modes span Laboratory Testing, Point Of Care Testing, and Research Use Only applications, reflecting the spectrum from clinically actionable diagnostics to exploratory and investigational assays. Taken together, these segmentation dimensions inform strategic prioritization for technology development, regulatory planning, and commercialization pathways, as trade-offs between sensitivity, speed, and operational fit differ across each segment and user class.

Regional dynamics and competitive positioning across the Americas, Europe, Middle East & Africa, and Asia-Pacific highlighting adoption, regulation, and capacity trends

Regional dynamics shape both the pace of technology adoption and the structure of diagnostic service delivery. In the Americas, high-capacity reference laboratories and integrated health systems drive demand for high-throughput platforms and consolidated workflows, while strong clinical research networks support pathway validation and early adoption of sequencing and mass spectrometry. Reimbursement complexity and regional procurement models, however, require clear demonstration of clinical utility and cost-effectiveness to support widespread deployment beyond tertiary centers.

In Europe, Middle East & Africa, heterogeneity in healthcare infrastructure results in a dual market pattern: advanced laboratories in urban centers and tertiary hospitals adopt cutting-edge molecular and proteomic platforms, while many settings continue to rely on robust culture and immunoassay workflows. Regulatory harmonization efforts in parts of Europe facilitate cross-border adoption, but diverse reimbursement landscapes and variable laboratory capacity in the broader region necessitate adaptable product designs and targeted implementation support.

In Asia-Pacific, rapid investments in laboratory capacity and a growing focus on infectious disease preparedness are creating fertile conditions for both centralized and decentralized diagnostics. Market dynamics in this region are influenced by a mix of large public health procurements and private sector laboratory expansion, offering opportunities for manufacturers that can scale supply and provide training and validation support. Across all regions, local manufacturing, supply chain resilience, and regulatory alignment are increasingly decisive factors that affect procurement cycles and the speed at which new technologies are integrated into routine practice.

Corporate intelligence and key company strategies shaping the fungal diagnostics ecosystem including innovation pathways, partnerships, and commercialization playbooks

The competitive landscape is characterized by a mix of established instrument and reagent manufacturers, specialized molecular and sequencing platform providers, contract research organizations, and emergent software and data analytics firms. Market leaders are differentiating through integrated solutions that combine robust instrument platforms with validated consumables, software-enabled workflow orchestration, and service agreements that reduce customer validation burdens. Mid-tier players often compete on niche assays, point-of-care formats, or cost-effective consumable models that fit specific laboratory segments.

Strategic collaborations and distribution partnerships are common, enabling companies to extend geographic reach and couple complementary technologies-such as linking a mass spectrometry identification system with a molecular resistance assay. Additionally, start-ups are introducing focused innovations in areas such as simplified sample preparation, rapid lateral flow formats with enhanced sensitivity, and bioinformatics tools that streamline NGS interpretation. Contract laboratories and reference testing networks play a pivotal role as early adopters and validators, providing pathways for new technologies to demonstrate clinical utility and drive broader laboratory adoption.

A clear pattern emerges where companies that invest in evidence generation, regulatory preparedness, and scalable service models are better positioned to secure long-term contracts with health systems. Moreover, firms that can offer training, remote support, and integration with laboratory information systems reduce friction for customers and accelerate uptake. Competitive advantage increasingly hinges on the ability to deliver end-to-end solutions that address analytical performance, operational efficiency, and the practical realities of laboratory validation and clinician adoption.

Actionable recommendations for industry leaders to accelerate clinical adoption, fortify supply chains, optimize portfolios, and capture value across diagnostic segments

Industry leaders should prioritize a set of strategic actions that accelerate clinical adoption while managing operational risks. First, invest in targeted clinical utility studies that link diagnostic outputs to actionable treatment decisions and measurable patient outcomes; robust clinical evidence reduces payer resistance and supports broader uptake. Second, diversify supply chains and consider regional manufacturing or strategic inventory buffering to mitigate tariff and logistics risks, ensuring continuity of testing services during policy-driven disruptions.

Third, align product development with end-user workflows by offering modular platforms that support both high-throughput centralized testing and rapid point-of-care use cases. This approach increases addressable use cases while allowing laboratories to scale adoption according to capacity. Fourth, strengthen partnerships with reference laboratories and clinical networks to facilitate third-party validation, early use-case documentation, and clinician education that can accelerate adoption curves. Fifth, embed software-driven value propositions-such as connectivity, result interpretation, and workflow automation-into offerings to reduce laboratory burden and improve result utility for clinicians.

Finally, engage proactively with regulatory bodies and payers to clarify evidence expectations and reimbursement pathways early in development. By anticipating regulatory and reimbursement questions and incorporating real-world evidence collection into rollouts, companies can shorten time-to-market and reduce adoption friction. These actions, taken together, create a resilient commercial strategy that balances innovation, evidence generation, and operational continuity.

Transparent research methodology outlining primary and secondary research approaches, data triangulation, validation protocols, and limitations informing the analysis

The analysis is founded on a mixed-methods research approach that integrates primary qualitative inquiry with systematic secondary evidence review and triangulation. Primary research included structured interviews with clinical laboratorians, hospital procurement leaders, research institute investigators, and industry executives to capture experiential insights into workflows, validation barriers, and adoption drivers. Secondary research encompassed peer-reviewed literature, regulatory guidance documents, clinical practice guidelines, and technology white papers to contextualize primary findings and to verify analytical assumptions.

Data triangulation was employed to reconcile disparate inputs and to identify consistent patterns across stakeholder groups and evidence sources. Technology mapping and capability assessments were performed to align platform characteristics with clinical use cases and laboratory operational constraints. Additionally, a review of clinical trial registries and patent filings informed the forward-looking view on innovation trajectories and emerging assay modalities.

The research recognizes limitations inherent to qualitative and secondary data, including variability in regional reporting, evolving regulatory landscapes, and the lag between technological development and published clinical validation. To mitigate these limitations, the analysis emphasizes corroborated themes and distinguishes between observed practice and aspirational capabilities. Where appropriate, sensitivity to regional heterogeneity and institutional capacity has been maintained to ensure that recommendations are actionable across diverse healthcare contexts.

Concise conclusion synthesizing implications for clinicians, laboratory leaders, investors, and policymakers to navigate the evolving fungal diagnostics landscape

Fungal diagnostics are in a period of substantive evolution where technological innovation, supply chain realignment, and evidence-driven adoption converge to reshape clinical practice. Laboratories and healthcare organizations face a complex landscape of choices that must balance analytical performance with operational realities and payer expectations. As molecular and proteomic platforms mature and point-of-care modalities broaden access, success will favor solutions that demonstrate tangible clinical impact while integrating smoothly into existing workflows.

Policy and procurement variables, such as tariffs and regional manufacturing dynamics, will continue to influence investment and adoption patterns. Stakeholders that proactively address these factors through diversified sourcing, strategic partnerships, and focused evidence generation will preserve continuity of diagnostic services and accelerate innovation uptake. Ultimately, sustained progress will depend on collaborative approaches that link manufacturers, clinical leaders, and health systems in shared efforts to validate, implement, and optimize diagnostic pathways for fungal disease.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of rapid molecular diagnostic panels into routine hospital workflows for fungal pathogens detection
• 5.2. Adoption of next-generation sequencing for comprehensive identification of rare and drug-resistant fungal species
• 5.3. Development of point-of-care immunoassays facilitating early detection of invasive fungal infections in outpatient settings
• 5.4. Rising demand for multiplex PCR technologies enabling simultaneous detection of multiple fungal pathogens in clinical samples
• 5.5. Expansion of telemedicine platforms incorporating remote diagnostic tools for monitoring chronic fungal infections
• 5.6. Growing interest in lateral flow assays for bedside detection of cryptococcal antigen among HIV patients
• 5.7. Regulatory approvals and reimbursement policies accelerating market access for novel beta-D-glucan diagnostic tests

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fungal Infections Diagnosis Market, by Diagnostic Technology

• 8.1. Culture Based
  • 8.1.1. Liquid Broth Culture
  • 8.1.2. Solid Media Culture
• 8.2. Immunoassays
  • 8.2.1. Elisa
  • 8.2.2. Lateral Flow Assay
• 8.3. MALDI TOF MS
• 8.4. Microscopy
• 8.5. Molecular Diagnostics
  • 8.5.1. Next Generation Sequencing
    • 8.5.1.1. Illumina Sequencing
    • 8.5.1.2. Ion Torrent Sequencing
  • 8.5.2. Polymerase Chain Reaction
    • 8.5.2.1. Conventional Polymerase Chain Reaction
    • 8.5.2.2. Real Time Polymerase Chain Reaction

9. Fungal Infections Diagnosis Market, by End User

• 9.1. Diagnostic Laboratories
• 9.2. Hospitals & Clinics
• 9.3. Research Institutes

10. Fungal Infections Diagnosis Market, by Specimen Type

• 10.1. Blood
• 10.2. Cerebrospinal Fluid
• 10.3. Sputum
• 10.4. Tissue
• 10.5. Urine

11. Fungal Infections Diagnosis Market, by Pathogen Type

• 11.1. Aspergillosis
• 11.2. Candidiasis
• 11.3. Cryptococcosis
• 11.4. Dermatophytosis
• 11.5. Mucormycosis

12. Fungal Infections Diagnosis Market, by Testing Mode

• 12.1. Laboratory Testing
• 12.2. Point Of Care Testing
• 12.3. Research Use Only

13. Fungal Infections Diagnosis Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Fungal Infections Diagnosis Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Fungal Infections Diagnosis Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Thermo Fisher Scientific Inc.
  • 16.3.2. Roche Holding AG
  • 16.3.3. Abbott Laboratories
  • 16.3.4. bioMerieux SA
  • 16.3.5. Becton, Dickinson and Company
  • 16.3.6. Bruker Corporation
  • 16.3.7. DiaSorin S.p.A.
  • 16.3.8. QIAGEN N.V.
  • 16.3.9. Siemens Healthineers AG
  • 16.3.10. Fujirebio Holdings, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. FUNGAL INFECTIONS DIAGNOSIS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 213. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 215. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 217. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 221. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 222. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 223. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 224. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 225. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
• TABLE 226. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
• TABLE 227. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 228. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 229. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2024 (USD MILLION)
• TABLE 230. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2025-2032 (USD MILLION)
• TABLE 231. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 232. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 233. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 234. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 239. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2024 (USD MILLION)
• TABLE 240. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2025-2032 (USD MILLION)
• TABLE 241. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 242. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 243. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 244. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 245. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 246. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 247. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
• TABLE 248. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
• TABLE 249. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2024 (USD MILLION)
• TABLE 252. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2025-2032 (USD MILLION)
• TABLE 253. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 254. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 255. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 256. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 257. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 260. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 261. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2024 (USD MILLION)
• TABLE 262. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2025-2032 (USD MILLION)
• TABLE 263. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 264. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 265. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 266. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 267. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 268. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 269. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
• TABLE 270. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
• TABLE 271. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 272. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 273. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2024 (USD MILLION)
• TABLE 274. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2025-2032 (USD MILLION)
• TABLE 275. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 276. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 277. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
• TABLE 278. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
• TABLE 279. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 280. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 281. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 282. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 283. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2024 (USD MILLION)
• TABLE 284. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2025-2032 (USD MILLION)
• TABLE 285. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
• TABLE 286. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
• TABLE 287. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 288. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 289. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 290. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 291. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS